Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

InnoCare Approved to Launch Cytolytic CD-19 Immunotherapy in Hong Kong

publication date: Dec 29, 2022

Beijing InnoCare Pharma was approved for a Hong Kong launch of tafasitamab, a humanized Fc-modified cytolytic CD19-targeting immunotherapy, in patients with diffuse large B-cell lymphoma (DLBCL). InnoCare acquired China rights to the candidate from Delaware-based Incyte in a $117 million deal last year. The drug will be administered in combination with lenalidomide to adult patients with relapsed or refractory forms of DLBCL who are not eligible for autologous stem cell transplant (ASCT). InnoCare promised it will speed up China tafasitamab trials to advance its approval in China’s mainland. More details....

Stock Symbols: (HK: 09969; SHA: 688428) (NSDQ: INCY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital